Back grey_arrow_rt.gif
 
 
Intermune HCV protease Starts Study in Europe
 
 
  "InterMune Presents New Preclinical Data On Its Hepatitis C Virus Protease Inhibitor At DDW"
 
Tuesday, May 23, 2006; Posted: 04:13 PM
 
(RTTNews) - InterMune, Inc. on Tuesday announced the presentation of research describing the preclinical characterization of ITMN-191, its orally available hepatitis C virus NS3/4A protease inhibitor, at the Digestive Disease Week meeting in Los Angeles. The company expects to submit a European Clinical Trial Authorization for ITMN-191 in the third quarter.
 
According to the presentation of the preclinical findings, ITMN-191 retains activity against variants that exhibit reduced sensitivity to other experimental hepatitis C virus protease inhibitors in development. A single variant was identified that shows diminished potency to ITMN-191. However, the variant is distinct from variants that have reduced sensitivity to other hepatitis C virus protease inhibitors. This demonstrates a favorable cross-resistance profile of ITMN-191 with other hepatitis C virus protease inhibitors currently in development.
 
Also at Digestive Disease Week, the chemical structure of ITMN-191 was revealed for the first time, demonstrating the distinguishing characteristics between ITMN-191 and other experimental HCV protease inhibitors.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org